Farxiga approved in the US for the treatment of paediatric type-2 diabetes
US patients aged 10 years and older can now benefit from Farxiga for type-2 diabetes.Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date.AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older.[1] The FDA approval was based on positive results from the paediatric T2NOW Phase III trial.[2] Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to